| A Study of Mosliciguat in Combination With Inhaled Treprostinil in PH-ILD (NCT07333183) | Pulmovant, Inc. | 2025-12-23 |
| A Trial of SHR-7787 Injection Combined With Other Anti-tumor Drugs in Patients With Malignant Solid Tumors (NCT07268040) | Shanghai Hengrui Pharmaceutical Co., Ltd. | 2025-12-23 |
| Placebo-controlled Study to Evaluate the Safety and Efficacy of GLK-221 Ophthalmic Solution in Subjects With Keratoconus (NCT07400952) | Glaukos Corporation | 2025-12-23 |
| Riluzole For Preventing Cognitive Dysfunction in Ca Pts Receiving Chemo (REFOCUS): Pilot Trial (NCT07447050) | University of California, Irvine | 2025-12-23 |
| Remdesivir for the Treatment of Upper Respiratory Tract Infection Due to RSV in Immunocompromised Individuals (NCT06817889) | Fred Hutchinson Cancer Center | 2025-12-23 |
| An Open-Label Extension Study of PGN-EDODM1 in People With Myotonic Dystrophy Type 1 (FREEDOM-OLE) (NCT07220603) | PepGen Inc | 2025-12-23 |
| Garsorasib In KRAS G12C Mutant Locally Advanced and Metastatic NSCLC (NCT07294261) | Sun Yat-sen University | 2025-12-23 |
| Safety and Efficacy of Paclitaxel Liposome Arterial Infusion Combined With Systemic Therapy for Second-Line Treatment of Advanced Liver Cancer (NCT07282509) | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 2025-12-23 |
| Prophylactic Anti-Seizure Medication vs No Anti-Seizure Medication for Patients With Primary Motor Cortex Brain Metastases (NCT07130786) | Ayal A. Aizer, MD | 2025-12-23 |
| Study of TN-001 Topical Eyedrops for Keratoconus (NCT07388069) | TheiaNova Ltd. | 2025-12-23 |
| Study of ARO-DIMERPA in Adult Participants With Mixed Hyperlipidemia (NCT07223658) | Arrowhead Pharmaceuticals | 2025-12-22 |
| Investigating Ovulation Inhibition for Use as a Contraceptive (NCT07365904) | Mylan Pharmaceuticals Inc | 2025-12-22 |
| Efficacy and Safety of ICP-332 Versus Placebo in Participants With Moderate to Severe Plaque Psoriasis (NCT07251998) | Beijing InnoCare Pharma Tech Co., Ltd. | 2025-12-22 |
| A Phase 1/2, Open-Label, Single and Multiple Ascending Dose Study of CRMA-1001 in Adults With Chronic Hepatitis B (NCT07200193) | nChroma Bio | 2025-12-22 |
| Phase 2A/B Efficacy and Safety of Dabogratinib in Participants With Low Grade Upper Tract Urothelial Carcinoma (NCT07265947) | Tyra Biosciences, Inc | 2025-12-22 |
| Psilocybin on Brain Mechanisms of Motivation in OUD (NCT06810310) | University of Pennsylvania | 2025-12-22 |
| A Phase III Randomized Study of TACE Plus an Oral Triple-Agent Cocktail Versus TACE Plus First-Line Targeted Immunotherapy in Unresectable Hepatocellular Carcinoma (NCT07309419) | Shanghai Zhongshan Hospital | 2025-12-22 |
| Efficacy and Safety of Anrikefon Injection for the Treatment of Postoperative Pain in Patients Undergoing Totally Laparoscopic Radical Distal Gastrectomy (NCT07330063) | Tianjin Medical University Cancer Institute and Hospital | 2025-12-22 |
| Romiplostim N01 Plus ATRA for Persistent Isolated Chemotherapy-Induced Thrombocytopenia After Complete Remission of Gynecologic, Breast, or Lung Solid Tumors (NCT07586826) | Peking University People's Hospital | 2025-12-22 |
| MP0317 in Combination With Chemoimmunotherapy in First Line Treatment for Patients With Advanced Biliary Tract Carcinoma (NCT07036380) | Centre Hospitalier Universitaire de Besancon | 2025-12-22 |
| Neoadjuvant Chemotherapy Combined With Finotonlimab in the Treatment of Locally Advanced Hypopharyngeal Carcinoma (NCT07248956) | Eye & ENT Hospital of Fudan University | 2025-12-22 |
| A Phase II Clinical Trial on the Efficacy and Safety of TQC3721 Inhalation Powder (NCT07252908) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2025-12-22 |
| Study of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis (NCT07298395) | Enveda Therapeutics | 2025-12-22 |
| Dostarlimab, Cisplatin and Etoposide in Combination With Radiotherapy in Sandwich Sequence for Small Cell Neuroendocrine Cervical Carcinoma (NCT07336147) | Chang Gung Memorial Hospital | 2025-12-22 |
| A Single-Arm, Phase II Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan in Second-Line and Subsequent Treatments for Advanced Thymic Epithelial Tumors (NCT07343453) | Sun Yat-sen University | 2025-12-22 |
| Furmonertinib Combined With Intrathecal Chemotherapy and Stereotactic Radiotherapy (SRT) for EGFR-Mutated NSCLC Patients With Brain Parenchymal and Leptomeningeal Metastases (NCT07304739) | Tianjin Medical University Cancer Institute and Hospital | 2025-12-22 |
| A Study to Investigate the Clinical Effect and the Safety of PRX-115 Infused Intravenously at Different Dosing Regimens, With and Without Methotrexate, Versus Placebo in Adults Gout Patients (RELEASE) (NCT07280156) | Protalix | 2025-12-22 |
| AEF0217 in Participants With Down Syndrome (NCT07334912) | Aelis Farma | 2025-12-22 |
| A Phase Ib/II Trial of HS-20110 Combination Therapies in Advanced Colorectal Cancer Patients. (NCT07283367) | Hansoh BioMedical R&D Company | 2025-12-22 |
| Romiplostim N01 Plus ATRA for Persistent Isolated Chemotherapy-Induced Thrombocytopenia After Complete Remission of Gastrointestinal Solid Tumors (NCT07586813) | Peking University People's Hospital | 2025-12-22 |
| A Prospective, Single-Arm, Exploratory Study of IBI363 in ES-SCLC Patients After Immunotherapy Progression (NCT07289048) | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 2025-12-20 |
| SHR-A1811 Plus Pertuzumab as Neoadjuvant Therapy for Early or Locally Advanced HR-Positive HER2-Positive Breast Cancer: A Prospective, Open-Label, Phase II Study (NCT07307287) | Tianjin Medical University Cancer Institute and Hospital | 2025-12-20 |
| The Value of GRPR PET Imaging for Diagnosis and Staging in Prostate Cancer (NCT07363382) | First Affiliated Hospital of Fujian Medical University | 2025-12-20 |
| An Exploratory Study of Pertuzumab and Trastuzumab in Combination With Palbociclib and Exemestane as Neoadjuvant Therapy for Triple-Positive Breast Cancer (NCT07299890) | Anhui Provincial Cancer Hospital | 2025-12-20 |
| Golidocitinib Combined With GemOx in RR PTCL (NCT07279584) | Ruijin Hospital | 2025-12-20 |
| Ayahuasca, Esketamine and PTSD (NCT07317206) | University of Sao Paulo | 2025-12-20 |
| Neoadjuvant SHR-1701 Plus Chemoradiotherapy for Locally Advanced Rectal Cancer (NCT07478731) | Hong Qiu | 2025-12-20 |
| SIB-RT Combined With CAPOX and PD-1 for High-Risk Rectal Cancer (NCT07297030) | Sun Yat-sen University | 2025-12-20 |
| An Exploratory Study on Individualized Neoadjuvant Treatment Regimens for Early HR+/HER2+ Breast Cancer (NCT07300215) | The First Affiliated Hospital of Bengbu Medical University | 2025-12-20 |
| Neratinib Combined With Fulvestrant and Eribulin in the Treatment ofHR+/HER2+ Advanced Breast Cancer (NCT07333937) | Xijing Hospital | 2025-12-20 |
| Obinutuzumab, Zanubrutinib, and Lenalidomide in First-line Treatment of Mantle Cell Lymphoma (NCT07261163) | Institute of Hematology & Blood Diseases Hospital, China | 2025-12-20 |
| ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod (NCT07284420) | argenx | 2025-12-19 |
| KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J) (NCT07252739) | Merck Sharp & Dohme LLC | 2025-12-19 |
| A Study to Assess the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of Intravenous Administration of ARGX-119 in Pediatric Participants Aged 5 to Less Than 18 Years With Spinal Muscular Atrophy (NCT07287982) | argenx | 2025-12-19 |
| Obinutuzumab for Remission Induction in Patients With Relapsing PR3-ANCA Granulomatosis With Polyangiitis (NCT06940661) | Assistance Publique - Hôpitaux de Paris | 2025-12-19 |
| A Study to Evaluate the Efficacy and Safety of TTYP01 Tablets in Early Symptomatic Alzheimer's Disease (NCT07252440) | Shanghai Auzone Biological Technology Co., Ltd. | 2025-12-19 |
| Phase 1 Trial of Arginine Hydrochloride for the Management of Diabetic Ketoacidosis in Type 2 Diabetes (NCT07167693) | David K Carroll | 2025-12-19 |
| Perioperative Cadonilimab Combined With Neoadjuvant Chemotherapy in Resectable Esophageal Squamous Cell Carcinoma (ESCC) (NCT07263919) | Akeso | 2025-12-19 |
| Phase II Trial of Single Agent Belzutifan or Pembrolizumab Versus Combination as Neoadjuvant Therapy in Clear Cell Renal Cell Carcinoma (BLAZE) (NCT07187778) | M.D. Anderson Cancer Center | 2025-12-19 |
| Study is to Assess the Safety and Tolerability of VTx-002 in Participants With ALS (NCT07287397) | Vector Y Therapeutics | 2025-12-19 |
| A Study of GS3-007a for Oral Suspension in the Diagnosis of Adult Growth Hormone Deficiency (AGHD) (NCT07259564) | Changchun GeneScience Pharmaceutical Co., Ltd. | 2025-12-19 |
| Tolerability and Efficacy of CBD Extract for RLS Treatment (NCT07224932) | University of Colorado, Denver | 2025-12-19 |
| Phase 1/2 Study of MZ-1866, an AAV-9 Gene Therapy Delivered by Intracerebroventricular Injection to Participants With Pitt Hopkins Syndrome (NCT07135050) | Mahzi Therapeutics | 2025-12-19 |
| Tuvusertib in Astrocytoma With ATRX Mutation (NCT07417761) | Grupo Español de Investigación en Neurooncología | 2025-12-19 |
| A Clinical Study of Islatravir and Ulonivirine for People With HIV-1 Who Have Not Been Treated Before (MK-8591B-062) (NCT07266831) | Merck Sharp & Dohme LLC | 2025-12-18 |
| Ruxolitinib in Previously Treated Idiopathic Multicentric Castleman Disease (NCT07085039) | University of Pennsylvania | 2025-12-18 |
| Trastuzumab Rezetecan in Advanced Solid Tumors Refractory to Standard Therapies (NCT07309770) | Sheng Zhang | 2025-12-18 |
| Autophagy Maintenance (AUTOMAIN) (NCT06971744) | Medical University of South Carolina | 2025-12-18 |
| The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas (NCT07285044) | Mayo Clinic | 2025-12-18 |
| Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Primary Sjogren Disease (NCT07281456) | National Institute of Dental and Craniofacial Research (NIDCR) | 2025-12-18 |
| PET Myocardial Fatty-acid Metabolic Imaging With XTR003 Injection and 18F-FDG to Assess Myocardial Viability in Ischemic Cardiomyopathy (NCT07443696) | Sinotau Pharmaceutical Group | 2025-12-18 |
| Refractory Advanced diGestive Neuroendocrine Carcinomas Treated With tARlatamab (NCT07061080) | Grupo Espanol de Tumores Neuroendocrinos | 2025-12-18 |
| A Study of Picankibart in Patients With Active Psoriatic Arthritis (NCT07295509) | Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. | 2025-12-18 |
| SYS6010 Combined With Enlonstobart In Recurrent Or Metastatic Head And Neck Squamous Cell Carcinoma (NCT07254585) | CSPC Megalith Biopharmaceutical Co.,Ltd. | 2025-12-18 |
| Fezolinetant for Treating Hot Flashes in Men With Prostate Cancer (NCT06972875) | University of Vermont | 2025-12-18 |
| Small Cell Lung Cancer Irinotecan and CDC2-like Kinase Inhibition Trial (SLICK Trial) (NCT07155200) | Washington University School of Medicine | 2025-12-18 |
| Phase II Study of EMB-01 in Recurrent/Metastatic Colorectal Cancer Patients (NCT07314294) | Shanghai EpimAb Biotherapeutics Co., Ltd. | 2025-12-18 |
| A Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive Disorder (NCT07276997) | AbbVie | 2025-12-18 |
| Stereotactic Body Radiotherapy With Sequential Iparomlimab and Tuvonralimab (QL1706) + Chemotherapy as Neoadjuvant Therapy in Patients With Resectable Non-small-cell Lung Cancer in China (LUNG-Nanjing01): a Single-arm, Single-centre, Phase 2 Trial (NCT07286942) | Jiangsu Cancer Institute & Hospital | 2025-12-18 |
| Effect of 2-HOBA in Persistent Immune Activation in Long COVID POTS (NCT07189936) | Vanderbilt University Medical Center | 2025-12-18 |
| A Phase II Study of CM326 in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease (NCT07418736) | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 2025-12-18 |
| Phase I/II Clinical Study of JMT108 Injection for the Treatment of Advanced Malignant Melanoma and Urinary Tract Tumors (NCT07280832) | Shanghai JMT-Bio Inc. | 2025-12-17 |
| A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid Tumors (NCT06956690) | Hummingbird Bioscience | 2025-12-17 |
| Olutasidenib With Azacitidine Followed by Olutasidenib Maintenance for the Treatment of IDH1-mutated Acute Myeloid Leukemia in Patients With Prior Treatment With Venetoclax Plus a Hypomethylating Agent (NCT07304011) | University of California, Davis | 2025-12-17 |
| A Study of OTP-01, a Dual Paratopic PD-1/VEGFR2 Antibody, in Patients With Advanced Solid Tumors (NCT07266428) | Ottimo Pharma Limited | 2025-12-17 |
| A Study of REGN7041 for Active Noninfectious Uveitis in Adult Participants (NCT07218770) | Regeneron Pharmaceuticals | 2025-12-17 |
| A Study of LAD603 in Adults With Alopecia Areata (NCT07311564) | Almirall, S.A. | 2025-12-17 |
| Therapeutic Equivalence of CHF5993 pMDI 100/6/12.5 µg HFA-152a in Subjects With Mild to Moderate Asthma (NCT07301736) | Chiesi Farmaceutici S.p.A. | 2025-12-17 |
| A Phase 2 Study to Evaluate the Efficacy and Safety of Pudafensine in Vulvodynia (Provoked Vestibulodynia) (NCT07391241) | Initiator Pharma | 2025-12-17 |
| Using a Fixed Dosage of Follitropin Delta for Ovarian Stimulation for Intrauterine Insemination: Rekovelle for Intrauterine Successful Experience (RISE) (NCT07153367) | Centre Hospitalier Intercommunal Creteil | 2025-12-17 |
| Role of GLP1 RA Dulaglutide on Severe Intracranial Atherosclerosis (NCT07282041) | National University of Singapore | 2025-12-17 |
| Psilocybin for Opioid Use Disorder (OUD) (NCT06796062) | NYU Langone Health | 2025-12-17 |
| Application of [68Ga]Ga-NI-FAPI-04 PET/CT Imaging in Fibroblast Activation Protein Related Diseases (NCT07464132) | Peking Union Medical College Hospital | 2025-12-17 |
| Brain Blood Vessel Responses to Changes in Blood Flow: Younger Cohort (NCT06629090) | University of Wisconsin, Madison | 2025-12-17 |
| Ipromlimab and Tuvonralimab Combined With Albumin-Bound Paclitaxel and Nedaplatin as Neoadjuvant Therapy for Locally Advanced Resectable Esophageal Squamous Cell Carcinoma (NCT07374003) | Sun Yat-sen University | 2025-12-17 |
| Phase II Trial of Neoadjuvant Thymalfasin, PD-1 Inhibitor, and Chemoradiotherapy for cStage III GEJ Adenocarcinoma (NCT07277439) | The First Affiliated Hospital with Nanjing Medical University | 2025-12-16 |
| DEPECA-1 - A Phase II Study to Evaluate a First-line Systemic Therapy With Enfortumab Vedotin Plus Avelumab for Advanced and Metastatic Penile Carcinoma (NCT07110038) | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | 2025-12-16 |
| A Phase Ⅰ/Ⅱa Study of HMPL-A251 in Participants With Advanced or Metastatic HER2-expressing Solid Tumors (NCT07228247) | Hutchmed | 2025-12-16 |
| Efficacy and Safety of SCT650C in Participants With Moderate to Severe Hidradenitis Suppurativa (NCT07244510) | Sinocelltech Ltd. | 2025-12-16 |
| Luspatercept + Darbepoetin in MDS (NCT07096297) | Yale University | 2025-12-16 |
| Futibatinib in Combination With (Chemo)Immunotherapy in Colorectal Cancer and Other Solid Tumor Entities (NCT06722183) | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | 2025-12-16 |
| HIV-1 Virologic Suppression With TMB-365 and TMB-380 Antibodies Study (NCT07215468) | TaiMed Biologics Inc. | 2025-12-16 |
| The KN510713 Study in Combination With mFOLFIRINOX (NCT07114861) | New Cancer Cure-Bio Co.,Ltd. | 2025-12-16 |
| A Study to Evaluate the Effectiveness of DT-101 in Patients With Depression (NCT07300969) | Draig Therapeutics Ltd | 2025-12-16 |
| A Phase II Trial of LM103 in Advanced Melanoma (NCT07310784) | Suzhou BlueHorse Therapeutics Co., Ltd. | 2025-12-16 |
| Ultralow Dose PET Imaging of 18F-flurpiridaz (NCT07284576) | Akiva Mintz | 2025-12-16 |
| DCSZ11 in Combination With Standard Therapy in Advanced or Metastatic Solid Tumors (NCT07035249) | West China Hospital | 2025-12-16 |
| Study of DONQ52 in Active Celiac Disease (NCT07239336) | Chugai Pharmaceutical | 2025-12-16 |
| Study to Evaluate the Effects of AV-001 on HD-induced Brain Injury. (NCT07234890) | London Health Sciences Centre Research Institute | 2025-12-16 |
| Resilience Enhancement Following Sleep Treatment (NCT07298941) | University of Virginia | 2025-12-16 |